ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2702

Key Roles for Mir-155 and Mir-21 in Progressive Lung Fibrosis Associated with Systemic Sclerosis (SSc-ILD)

Romy Christmann1, Percival D Sampaio-Barros2, Claudia Borges3, Carlos Carvalho4, Ronaldo A Kairalla5, Edwin R. Parra6, Giuseppina Stifano7, Avi Spira8, Robert W. Simms9, Vera L. Capelozzi6 and Robert Lafyatis10, 1Rheumatology, Arthritis Center/Rheumatology, Boston, MA, 2Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 3Rheumatology, CEUMA University, Sao Luis do Maranhao, Brazil, 4Pulmonology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil, 5Division of Pulmonology - Heart Institute (InCor) - Medical School, University of Sao Paulo, Sao Paulo, Brazil, 6Pathology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil, 7Rheumatology, Boston University Medical Center, Boston, MA, 8Boston University School of Medicine, Boston, MA, 9Rheumatology, Boston University School of Medicine, Boston, MA, 10Arthritis Center, Boston University, Boston, MA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Lung Disease, MicroRNA and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics: Determinants of Disease, Classification and Response

Session Type: Abstract Submissions (ACR)

Background/Purpose

We have already reported that macrophage activation, and up-regulation of TGF-beta- and interferon-regulated genes are involved in progressive SSc-ILD. Micro-rnas (miRNA) are a class of small noncoding RNAs that control gene expression and are eventually involved in most biological processes. Therefore, we analyzed simultaneously mRNA and miRNA in the same prospective cohort of SSc-ILD patients in order to explore their complex network and the miRNA’s involvement in progressive lung disease.

Methods

Lung tissue was obtained by open lung biopsy in 22 consecutive SSc-ILD patients (11 diffuse and 10 limited cutaneous SSc patients; 5 controls). High-resolution computerized tomography (HRCT) was performed on baseline and 2-3 years after treatment that was based on lung histologic classification. Microarray analysis (mRNA and miRNA) was performed and the results correlated (Pearson’s) with changes in HRCT score (FibMax). MirConnX software was used to explore the gene regulatory network between mRNA and miRNA. The study was approved by the Institutional Review Boards from both universities (Brazil and USA).

Results

As already shown, despite treatment, most of SSc-ILD patients progressed based on delta FibMax (p< 0.01). Lung miRNA microarray analysis distinguished SSc-ILD from controls (FDR-corrected, q<0.25) with 185 miRNA genes (present in ³25%) that had significant differential expression. The mRNA microarray analysis also confirmed the altered expression of hundreds of genes in our SSc-ILD cohort and MirConnX simultaneous analysis of mRNA and miRNA showed 4 relevant miRNAs in the center of this multifaceted regulation (graphic): mir-182, mir-141, mir-155, and mir-195 (graphic). Pearson’s correlation between miRNAs and the top-50 most upregulated mRNAs in SSc-ILD compared to controls showed that mir-155 was strongly correlated (r>0.5) with 32/top-50 genes, such as IL13Ra2 (r=0.75) and TOP2A (r=0.68), mir-21 was the second most correlated (22/top-50 genes), followed by mir-195 (21/top-50 genes), mir-141 (22/top-50 genes), and mir-182 (19/top-50 genes). Mir-155 and mir-21 were also strongly negatively correlated with several top-downregulated mRNA genes, including IL12A, with r=-0.70. A heatmap of the most informative miRNAs showed mir-155 clustering together with mir-21, a known miRNA involved in idiopathic lung fibrosis; and both mir-155/mir-21 expression were strongly correlated (r2=0.6). Surprisingly, only 4 miRNAs were correlated to the delta FibMax: mir-155 (r=0,65), mir-182 (r=0.49), mir-27a (r=0.49), and mir-21 (r=0.47).

Conclusion

Mir-155 and mir-21 were the center of this complex altered gene expression in the lungs of SSc-ILD. More importantly, these miRNAs were key for the progression of the lung fibrosis based on a CT score. Together, anti-miRNA therapy might be a novel target to prevent progressive SSc-ILD.

Mirconnx.jpg


Disclosure:

R. Christmann,
None;

P. D. Sampaio-Barros,
None;

C. Borges,
None;

C. Carvalho,
None;

R. A. Kairalla,
None;

E. R. Parra,
None;

G. Stifano,
None;

A. Spira,
None;

R. W. Simms,
None;

V. L. Capelozzi,
None;

R. Lafyatis,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/key-roles-for-mir-155-and-mir-21-in-progressive-lung-fibrosis-associated-with-systemic-sclerosis-ssc-ild/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology